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Background: The PIAS4 protein belongs to the family of protein inhibitors of activated STAT, but has since been implicated in
various biological activities including the post-translational modification known as sumoylation. In this study, we explored the roles
of PIAS4 in pancreatic tumourigenesis.
Methods: The expression levels of PIAS4 in pancreatic cancer cells were examined. Cell proliferation and invasion was studied
after overexpression and gene silencing of PIAS4. The effect of PIAS4 on hypoxia signalling was investigated.
Results: The protein was overexpressed in pancreatic cancer cells compared with the normal pancreas. Gene silencing by PIAS4
small interfering RNA (siRNA) suppressed pancreatic cancer cell growth and overexpression of PIAS4 induced expression of genes
related to cell growth. The overexpression of PIAS4 is essential for the regulation of the hypoxia signalling pathway. PIAS4
interacts with the tumour suppressor von Hippel-Lindau (VHL) and leads to VHL sumoylation, oligomerization, and impaired
function. Pancreatic cancer cells (Panc0327, MiaPaCa2) treated with PIAS4 siRNA suppressed expression of the hypoxia-inducible
factor hypoxia-inducible factor 1 alpha and its target genes JMJD1A, VEGF, and STAT3.
Conclusion: Our study elucidates the role of PIAS4 in the regulation of pancreatic cancer cell growth, where the suppression of its
activity represents a novel therapeutic target for pancreatic cancers.
Pancreatic adenocarcinoma (PDAC) has become one of the leading
causes of death in industrialised countries (Vincent et al, 2011). It
is usually diagnosed at late stages, where curative surgery provides
poor prognosis, and other forms of therapy including chemother-
apy lack efficacy (McCarthy, 2009; Colucci et al, 2010). Continuing
efforts have been made to identify both biomarkers for early
diagnosis and molecular targets for therapy (Natoni et al, 2005;
Adachi et al, 2010). Emerging studies show that protein
sumoylation by small ubiquitin-related modifier (SUMO) proteins
is an important post-translational modification in regulating the
biological activities of proteins (Jackson, 2001). Sumoylation
involves sequential actions by E1-activating enzyme, E2-conjugat-
ing enzyme, and E3 protein ligase (Wilkinson and Henley, 2010).
Both positive and negative effects on protein functions by
sumoylation have been reported (Depaux et al, 2007; Karamouzi
et al, 2008). PIAS4 (protein inhibitor of activated STAT protein 4)
is an E3-type SUMO ligase. It interacts with and suppresses the
biological activity of the tumour suppressor protein von Hippel–
Lindau (VHL) in renal clear-cell carcinoma (Sachdev et al, 2001).
Sumoylation of VHL mediated by PIAS4 results in the formation
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of VHL oligomers, which in turn reduces its tumour suppressor
activity against hypoxia-inducible factor 1 alpha (HIF1a) (Cai et al,
2010; Cai and Robertson, 2010). Hypoxia has an essential role in
tumourigenesis and metastasis of solid tumours including PDAC
(Denko, 2008; Wilson and Hay, 2011). We found that PIAS4 is
highly expressed in PDAC cell lines and tumours, and small
interfering RNA (siRNA) against PIAS4 suppressed their pro-
liferation. Our study demonstrates for the first time that PIAS4
may also constitute a therapeutic target against pancreatic cancer.
MATERIALS AND METHODS
Cell culture. Fourteen pancreatic cancer cell lines (AsPc1 BxPc3,
Panc1, Panc0203, Panc0327, Panc0403, Panc0504, Panc0813,
Panc1005, CFPAC1, CaPan2, MiaPaCa2, PL45, and SU8686) were
obtained from the American Type Culture Collection (Manassas,
VA, USA). All the cell lines were maintained in either DMEM or
RPMI-1640 supplemented with 10% FBS. For the induction of
hypoxia, cells were incubated in temperature-controlled hypoxic
culture chambers at 1% O2, 5% CO2, and 94% N2.
Small interfering RNAs. Scrambled control siRNA and PIAS4-
targeted siRNA mixtures (pool of 4) were purchased from Cell
Signalling (Boston, MA, USA). Non-target negative control (NC)
and exon-specific targeted siRNAs (siEXON2 and siEXON6 for
exons 2 and 6, respectively) were from IDT (Coralville, IA, USA).
Duplex sequences were NC: 50-CGUUAAUCGGUAUAAUACG
CGUAT-30, 50-CAGCAAUUAGCGCAUAUUAUGCGCAUA-30;
siEXON2: 50-GCUCUACGGAAAGUACUUAAACGGA-30, 50-U´C
CGUUUAAGUACUUUCCGUAGAGCAC-30; siEXON6: 50-ACC
UCACUCACCUCAUGUACCUGT-30, 50-GACAGGUACAUGAG
GUGAGUGAGGUUG-30). RNAiMAX (used for siRNA transfec-
tion) and Lipofectamine 2000 (used for plasmid DNA over-
expression) were from Invitrogen (Carlsbad, CA, USA).
Public databases. Oncomine (Compendia Bioscience, Ann Arbor,
MI, USA) and the Human Protein Atlas were used for analysis and
visualisation.
MTT assays. A total of 3000 pancreatic cancer cells were plated in
96-well plates and cultured for various durations as indicated. Cell
viability was assayed using MTT (3-(4,5- Dimethylthiazol- 2- yl)-
2,5-diphenyltetrazolium bromide) and calculated with BioDataFit
GraphPad Prism software (Castro Valley, CA, USA).
Colony formation and invasion assays. For colony assays, equal
number of cells was seeded in 24-well plates at 24 h after siRNA
transfection and 72 h later, the colonies were stained with 0.1%
crystal violet in 50% methanol and quantified by measurement of
optical density at 540 nm after dissolving the cells in 20% acetic
acid. For migration assays, cells were serum-starved overnight and
equal numbers of cells were plated on cell culture inserts with 8mm
membrane (Boyden chambers from Millipore, Billerica, MA, USA)
in 24-well plates. After 24 h incubation, cells that did not pass
through the filter were removed with a cotton swab, and the
culture inserts were stained with 0.1% crystal violet in 50%
methanol and photographed.
Real-time reverse transcription PCR. Total RNA from cell lines,
as well as from tissue per IRB protocol, was extracted using
Invitrogen Trizol and cleaned up with Qiagen RNase kit (Hilden,
Germany). All RNAs after extraction were treated with DNase to
remove genomic DNA. First strand cDNA synthesis kit from
Fermentas (Waltham, MA, USA) was used to prepared cDNA
from 2 to 5 mg RNA. Real-time PCR was performed using SYBR
Green PCR ready-mixed reagents from Fermentas in Applied
Biosystems 7500 Fast PCR system (Foster City, CA, USA). All PCR
reactions were performed in triplicates. PCR products were
checked for specificity on a 2% agarose gel. Expression levels of
GAPDH were used as internal controls to calculate relative target
gene expression levels.
Immunoprecipitation assays. Cells were co-transfected with
PIAS4 and different VHL expression vectors by Invitrogen
Lipofectamine 2000. At 48 h after transfection, cells were lysed
with lysis buffer containing 50mM Tris, pH 7.6, 5mM EDTA,
300mM NaCl, 1mM dithiothreitol, and 0.1% Nonidet P-40 with
Fermentas protease inhibitors. For immunoprecipitation, the
cell lysates were incubated with antibody at 4 1C for 2 h, and
the immunoprecipitated complexes were bound to protein
A/G-Sepharose beads from Invitrogen at 4 1C overnight. The
beads were washed four times with lysis buffer, and proteins were
eluted in sample buffer and resolved on 10% SDS–PAGE for
western blot analysis. Von Hippel–Lindau expression vectors
included pCSVHL-WT, pCSVHL-W88S, pCSVHL-Y112H, and
pCSVHL-R167Q.
Western blot analysis. Protein lysates were prepared using the
Fermentas ProteoJET Mammalian Cell Lysis Reagent according to
the manufacturer’s protocol. Twenty micrograms of protein lysates
were used in SDS–PAGE followed by western blot transfer.
Antibodies (phospho-NFkB, phospho-GSK3b, phospho-STAT3;
phospho-ERK, MYC, Cyclin D1, a-tubulin, VHL; GAPDH;
PIAS4, HIF1a) were purchased from Cell Signaling (Boston, MA,
USA), Santa Cruz (Santa Cruz, CA, USA), Sigma-Aldrich
(St. Louis, MO, USA ), and Novus (Littleton, CO, USA). SuperSignal
West Dura or West Femto chemiluminescent substrates from Pierce
(Rockford, IL, USA) were used to detect the immunocomplexes.
Reporter assays. For Myc reporter assays, cells at subconfluent
density in 12-well plates were co-transfected with 1mg of Myc-LUC,
25 ng of Renilla luciferase pRL-TK transfection control and 1 mg of
either PIAS4 expression vector (pCMV-PIAS4) or empty vector
(pCMV). The Myc reporter construct (Myc-LUC) contains 700 bp
of c-Myc promoter cloned upstream of the firefly luciferase cDNA.
Reporter activities were determined using the Dual Luciferase
Assay Kit from Promega (Fitchburg, WI, USA). Results were
calculated from triplicates of two independent experiments. For
hypoxia-response element reporter assays, HRE-LUC was used,
which contains three repeats of the hypoxia-response element
upstream of the thymidine kinase minimal promoter driving the
luciferase reporter. The cells were co-transfected with HRE-LUC
and pCMV-PIAS4, and either pCSVHL-WT, pCSVHL-W88S,
pCSVHL-Y112H, pCSVHL-R167Q or pCS, with Renilla luciferase
pRL-TK as a transfection control.
RESULTS
Expression levels of PIAS4 are elevated in pancreatic cancer cells
compared with normal pancreas. The expression of PIAS4 in
12 pancreatic cancer cell lines and 11 pancreatic tumours, as well
as 6 normal pancreas samples was assessed by real-time reverse
transcription PCR (RT–PCR). Elevated levels of PIAS4 occurred in
pancreatic cancer cell lines and tumours compared with normal
pancreas with a mean increase of three-fold in pancreatic cancer
cell lines and six-fold in fresh pancreatic tumours (P¼ 0.0154)
(Figure 1A). Immunohistochemistry analysis showed that PIAS4
was strongly expressed in pancreatic tumours compared with
surrounding pancreatic parenchyma (Figure 1B). This observation
was corroborated by mining public databases. The Oncomine
expression data showed upregulation of PIAS4 transcript in
pancreatic ductal adenocarcinoma (Supplementary Figure 1;
Buchholz et al, 2005). The Human Protein Atlas reported positive
PIAS4 staining in both the cytosol and membrane of pancreatic
tumours and negative staining in normal pancreas (Supplementary
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Figure 2; Uhlen et al, 2010). The expression of PIAS4 protein was
further quantified in 14 pancreatic cancer cell lines by western blot
analysis. High or moderate expression of PIAS4 was detected in
Panc0203, Panc0327, Panc0403, Panc1005, MiaPaCa2, and CFPAC
human pancreatic cancer cell lines (Figure 1C).
Gene silencing by PIAS4 siRNA suppressed cell growth in
human pancreatic cancer cells; whereas PIAS4 overexpression
induced cell growth genes. To test the role of endogenous PIAS4
in cell proliferation, two cell lines (Panc0327 and Panc1005) with
high and two (AsPc1 and BxPc3) with low PIAS4 expression were
used for siRNA transfection first with PIAS4 siRNA mixture
containing a pool of four siRNAs and compared with scrambled
control siRNA. Liquid culture proliferation assays showed that
pancreatic cancer cells transfected with PIAS4 siRNA had slower
cell growth compared with two controls (wt: wild-type; ctrl siRNA:
control siRNA) (Figure 2A). Also, colony assays of Panc0327 and
Panc1005 showed decreased colony number in cells transfected
with PIAS4 siRNA compared with either wild-type cells or
cells transfected with control scrambled siRNA (ctrl siRNA)
(Figure 2B). In addition, we tested two extra siRNA targeting either
exon 2 (siEXON2) or exon 6 (siEXON6) of PIAS4 in these
pancreatic cancer cells. We found that pancreatic cancer cell lines
transfected with both of these siRNAs suppressed cell proliferation
compared with either NC (non-target siRNA NC) or wild-type
cells (Figure 2C).
Exogenous PIAS4 was expressed in a low PIAS4-expressing
pancreatic cancer cell line (Panc1) to examine its effect on pancreatic
cancer cells. Proteins related to cell cycle and cell proliferation
(Cyclin D1, MYC, phosphorylated ERK, and phosphorylated
GSK3b) were increased in Panc1 cells transfected with pCMV-
PIAS4 compared with cells transfected with the empty vector
(Figure 2D). In addition, the phosphorylation level of NFkB/p65 was
elevated after overexpression of PIAS4 in Panc1 cells, suggesting the
activation of the NFkB signalling pathway by PIAS4 (Figure 2D).
Also, MYC reporter assays showed more than 15-fold induction of
the MYC promoter activity in pancreatic cancer cells transfected
with the PIAS4 expression vector compared with cells transfected
with the empty vector (Figure 2E).
Hypoxia-inducible factor 1 alpha is regulated by PIAS4 via
sumoylation of VHL. Because pancreatic cancer frequently occurs
in a low oxygen environment, we examined the expression levels
of PIAS4 and HIF1a mRNA under hypoxic conditions (1% O2).
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Figure 1. Expression of PIAS4 in human pancreatic cancer cell lines, pancreatic tumours, and normal pancreas. (A) Relative RNA expression levels
of PIAS4 as a mean of 12 pancreatic cancer cell lines, 11 tumor samples, and 6 normal pancreas. The relative PIAS4 RNA expression level in each
sample was normalised to that of GAPDH. *compared with the normal pancreas, P¼ 0.0154. (B) Immunohistochemistry analysis of PIAS4 in normal
pancreas and pancreatic tumor. (C) Western blot analysis of PIAS4 protein expression in 14 pancreatic cancer cell lines. The arrow indicates the
band corresponding to the PIAS4 protein. GAPDH was used as a loading control.
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Real-time RT–PCR showed that PIAS4 and HIF1a were induced
15- to 20-fold by hypoxia in Panc0327 and Panc1005 within 4 h
(Figure 3A). The induction levels were less in BxPc3 and AsPc1
pancreatic cancer cell lines at 4- to 8-fold but still significant
(Figure 3A). We investigated the protein expression levels of HIF1a
and PIAS4, as well as STAT3, a modulator of cell proliferation
mediated by HIF1a, in BxPc3 cells under hypoxia. After 2 h
exposure to 1% O2, acute induction of HIF1a was associated with
the induction of phosphorylated STAT3; and this induction of
both proteins was diminished after 48 h of 1% O2 exposure
(Figure 3B). The PIAS4 protein level was also induced after 2 h
exposure to hypoxia, and the expression levels remained elevated
under chronic hypoxia conditions (48 h, 1% O2,) (Figure 3B). In
addition, we explored the role of PIAS4 in NFkB, AKT, and
MAPK pathways under hypoxic condition. Increase in phosphor-
ylation levels of AKT and ERK was associated with the induction
of HIF1a and phosphorylated STAT3 after 2 h exposure to 1% O2;
and levels of these activated proteins decreased after 48 h of 1%
O2 exposure. On the other hand, NFkB exhibited significant basal
phosphorylation which decreased after acute and chronic hypoxia
(Figure 3B).
A previous study in renal cell carcinoma cells showed that
PIAS4 siRNA increased the degradation of HIF1a by activation of
VHL. Initially, we investigated the effect of PIAS4 siRNA on levels
of HIF1a at normoxia conditions. Knockdown of PIAS4 in
MiaPaCa2 pancreatic cancer cells decreased levels of HIF1a as
well as expression of the HIF1a target gene VEGF (Figure 4A).
Surprisingly, VHL expression level was also suppressed by PIAS4
siRNA in these cells (Figure 4A), suggesting another mechanism of
VHL regulation by PIAS4. Because pancreatic cancer cells are
highly invasive, the effect of PIAS4 knockdown was studied using
Boyden chamber assays. The MiaPaCa2 cells transfected with
PIAS4 siRNA exhibited both suppression of cell proliferation on
adherent cells and decreased cell invasion through Boyden
chambers compared with wild-type and control siRNA transfected
cells (Figure 4B). Furthermore, we examined the effect of PIAS4
siRNA on the HIF1a pathway under hypoxic conditions (1% O2)
in MiaPaCa2 cells. Real-time RT–PCR showed that the induction
of both VEGF and another HIF1a target gene, JMJD1A, were
suppressed after PIAS4 siRNA transfection in MiaPaCa2 cells
compared with the two control conditions (wild-type untransfected
and control siRNA transfected) (Figure 4C).
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Figure 2. Effect of silencing and overexpression of PIAS4. (A) Four pancreatic cancer cell lines (AsPc1, BxPc3, Panc0327, and Panc1005) were
transfected with either mock transfection (wild-type, wt), control siRNA (ctrl siRNA) or pooled PIAS4 siRNA. MTT assays show the effect of PIAS4
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Next, we examined the effect of PIAS4 siRNA on the protein
expression levels of HIF1a and STAT3 in pancreatic cancer cells
(MiaPaCa2 and Panc0327) in hypoxic conditions (1% O2,). In the
two control conditions (wild-type and control siRNA), the
induction of HIF1a protein was readily detectable after exposure
to hypoxia for 2 h (Figure 5A and B). The expression levels of the
induced HIF1a protein continued to be robustly expressed even
after 48 h exposure to hypoxia in these cells with control siRNA
(Figure 5A and B). In PIAS4 siRNA knockdown cells, the
induction levels of HIF1a were either decreased as in MiaPaCa2
cells (Figure 5A) or the HIF1a induction was markedly delayed
with prominent expression only after 48 h exposure to hypoxia in
Panc0327 cells compared with controls (Figure 5B). The
phosphorylation level of STAT3 was prominently diminished in
PIAS4 siRNA transfected cells, and chronic hypoxia (48 h) was
unable to induce STAT3 phosphorylation in these cells (Figure
5A and B).
The protein level of HIF1a can be regulated by VHL-mediated
degradation; and E3 ubiquitin ligase activity of VHL can be
affected by its levels of sumoylation. In MiaPaCa2 pancreatic
cancer cells treated with PIAS4 siRNA, the levels of SUMO1 in
total cell lysates were decreased as shown by western blot analysis
(Figure 6A) when PIAS4 was knocked down by490% (Figure 6B),
Immunoprecipitation experiments showed that PIAS4 and VHL
interacted, and as expected this interaction was diminished after
PIAS4 siRNA was transfected into MiaPaCa2 cells (Figure 6C).
When the same western blot was probed with VHL antibodies,
the sumoylation levels of VHL were increased under hypoxic
conditions in the two control cells (wild-type and ctrl siRNA
transfected) but the sumoylation was suppressed in PIAS4 siRNA-
treated cells (Figure 6D). Although the real-time PCR results
demonstrated decreased levels of VHL after siRNA treatment
(Figure 4A), no decrease in the levels of VHL protein occurred in
these cells (Figure 6D).
Prior investigators described (Cai et al, 2010) that the binding
domain of PIAS4 for VHL was between amino acids 54 and 120.
We used two VHL expression vectors containing mutations
in this region (pCSVHL-W88S; pCSVHL-Y112H) and one
mutation outside of this region (pCSVHL-R167Q) to examine
the binding between VHL and PIAS4. Co-expression of PIAS4
and wild-type VHL again showed binding between them and
this interaction was lost when wild-type VHL was replaced
with VHL containing mutations in the PIAS-binding region
(W88S and Y112H) (Figure 7A). The binding was retained
when the VHL mutation occurred outside of the PIAS4-binding
region (R167Q) (Figure 7A). Interaction between VHL and
PIAS4 was able to regulate HIF1a activity in a reporter
assay containing the hypoxia-response element (HRE-LUC)
(Figure 7B). The loss of the interaction between VHL and PIAS4
subsequently suppressed the induction of HIF1a activity
(Figure 7B). In addition, we found that mutation of VHL at
amino acid 167 also suppressed the hypoxia-response element
(reporter assays) (Figure 7B), although it did not disrupt the
interaction between PIAS4 and VHL.
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DISCUSSION
In this study, we demonstrated for the first time that PIAS4 is a
potential anticancer target in pancreatic cancer cells by regulating
HIF1a signalling through interaction and sumoylation of VHL.
PIAS4 belongs to the PIAS protein family, which includes PIAS1,
PIAS2 (or PIASX), PIAS3, and PIAS4 (or PIASg). They share
sequence homology and were initially characterised as protein
inhibitors of activated STAT proteins (Jackson, 2001). Subsequent
studies showed that the PIAS family of proteins modulated
transcription by different mechanisms, such as regulation of
DNA-binding activity of transcription factors, recruitment of
either corepressors or coactivators or engage in post-translational
modification by their SUMO E3 ligase activity (Bischof et al, 2006;
Wilkinson and Henley, 2010). In the non-small cell lung
carcinoma cell line H1299, PIAS4 interacted with p53 and
inhibited p53-mediated transactivation of its target genes BAX
and p21, although it did not inhibit apoptosis (Nelson et al, 2001).
In the prostate cancer cells LNCaP, PIAS4 interacted with the
DNA-binding domain of the androgen receptor (AR) and acted as
a transcriptional corepressor of AR which is central to prostate
cancer development and progression (Gross et al, 2004). Condi-
tional expression of PIAS4 induced apoptosis in a human chronic
myeloid leukaemia cell line KCL22 (Ohmine et al, 2001). However,
in synovial sarcomas, PIAS4-mediated sumoylation resulted in
overexpression of nuclear receptor coactivator 3, which is essential
for tumour formation (Sun et al, 2011). In hepatocellular
carcinoma HepG2 cells, PIAS4 modulates sumoylation of NEMO
(NF-kB essential modulator), and NF-kB activation in response to
DNA damage and knockdown of PIAS4 by siRNA in these cells
inhibited NF-kB activation (Mabb et al, 2006).
Our examination of PIAS4 expression in a panel of 14
pancreatic cancer cell lines and tumours indicated that dysregula-
tion of PIAS4 frequently occurred in pancreatic cancers.
Substantial increase in the PIAS4 protein expression levels was
found in tumour tissues compared with normal pancreatic
epithelium. By gene silencing of PIAS4 with siRNA, we demon-
strated that inhibition of PIAS4 with either pooled siRNAs or
individual siRNA targeting specific exons in four cell lines was
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associated with decrease in cell number. Also, knockdown of
PIAS4 in pancreatic cancer cells suppressed cell invasiveness as
measured by Boyden chamber assays. Forced expression of PIAS4
in one cell line (Panc1) resulted in induction of genes related to cell
growth such as Myc. A Myc reporter assay demonstrated that
PIAS4 activated the Myc promoter. C-Myc is a target of the
LEF/TCF transcription factor (Koenig et al, 2006). PIAS4 may
either directly stimulate the Myc promoter or acts as a coactivator
of LEF/TCF, which subsequently enhances transcription of Myc.
In a previous study in COS cells, PIAS4 colocalised with TCF in the
nucleus, sumoylated TCF, and activated TCF transcription (Ihara
et al, 2005). In addition, we found that overexpression of PIAS4
caused an increase, albeit subtle, in phosphorylation of NFkB/p65
in Panc1 pancreatic cancer cells. We were unable to detect
phosphorylated IKKb or IkBa, which suggests that this signalling
pathway is not robust in Panc1 cells. Previous studies showed that
upon DNA damage, PIAS4 caused NF-kB activation in HepG2
cells (Mabb et al, 2006), but inhibited NF-kB activity in skin
squamous cell carcinomas (Albor and Kulesz-Martin, 2007).
Pancreatic adenocarcinoma exists in a hypoxic microenviron-
ment (Couvelard et al, 2008), and by real-time RT–PCR, we
showed that PIAS4 was inducible together with HIF1a under
hypoxic conditions (1% O2). Induction of PIAS4 positively
correlated with levels of HIF1a in acute hypoxic conditions. Two
pancreatic cancer cell lines (AsPc1 and BxPc3) had low levels and
two (Panc0327 and Panc1005) had higher levels of induction of
both PIAS4 and HIF1a. In contrast, with chronic hypoxia, the
kinetics of PIAS4 and HIF1a induction were divergent. For
example, elevated levels of PIAS4 mRNA and protein paralleled
each other in BxPc3 cells after both acute and chronic exposure to
hypoxia. On the other hand, HIF1a RNA was continuously
increased during a 4- to 24-h period of hypoxia, but its protein
accumulation diminished at 48 h of hypoxia in the BxPc3 cells and
Panc0327 (data not shown). Phosphorylation levels of AKT and
ERK also exhibited similar kinetics as HIF1a. These data suggest
that regulation of HIF1a signalling by PIAS4 may be an acute
response to hypoxia; and additional regulatory mechanisms are
involved in chronic hypoxic conditions. Notably, NFkB exhibited
significant basal phosphorylation which decreased after acute and
chronic hypoxia. We suspect that this represents crosstalk
regulation between signallings of NFkB and HIF1a.
An earlier study of colon cancer demonstrated high PIAS4
expression with little angiogensis in colon cancer tissue, which was
associated with enhanced HIF1a sumoylation and deactivation of
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Figure 5. Effects of PIAS4 siRNA on HIF1a and phosphorylated STAT3
under hypoxic conditions. (A) MiaPaCa2 and (B) Panc0327 cells were
transfected with either control siRNA or PIAS4 siRNA and incubated in
a hypoxic chamber (1% O2) for 2 and 48h. Total protein lysates were
harvested for western blot analysis. GAPDH antibody was used as
loading control.
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Figure 6. Effects of PIAS4 siRNA on sumoylation, and interaction of
PIAS4 with VHL. MiaPaCa2 cells were transfected with either control
siRNA or PIAS4 siRNA, and cultured in 1% O2 for 0, 2, and 48h.
(A, B) Western blot analysis (IB) of total cell lysates for expression levels
of sumoylation (SUMO-1) and PIAS4. (C, D) Cell lysates were
immunoprecipitated (IP) with VHL antibodies and western blotted
(IB) with either PIAS4 or VHL antibodies. ctrl siRNA, control siRNA.
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HIF1a activity (Kang et al, 2010). By contrast, our study showed
that induction of PIAS4 is positively correlated with induction of
HIF1a. In the hypoxia signalling cascade, HIF1a activates down-
stream target genes including VEGF and JMJD1A and promotes
tumourigenesis (Tang et al, 2004; Krieg et al, 2010). Our real-time
RT–PCR results showed that PIAS4 siRNA suppressed the
expression of HIF1a in pancreatic cancer cells; and when these
cells were exposed to hypoxia for 48 h, the induction of the HIF1a
downstream targets, VEGF and JMJD1A, was also attenuated
during PIAS4 knockdown. The histone demethylase JMJD1A is a
member of the jumonji domain-containing family; and its function
is oxygen-dependent and regulated by HIF1a (Beyer et al, 2008).
JMJD1A has been identified as a useful biomarker for hypoxic
tumour cells such as colorectal and renal cell carcinomas (Beyer
et al, 2008; Uemura et al, 2010; Guo et al 2011). Alternatively,
PIAS4 may directly regulate JMJD1A, and the study of the ability
of PIAS4 to modulate epigenetic histone modifications via JMJD1A
will be of interest.
Another important protein involved in hypoxic signalling is
STAT3 (Gray et al, 2005). In cancers of diverse origins, the
activities of both STAT3 and HIF1a are upregulated in part by an
autocrine loop (Lang et al, 2007; Anglesio et al, 2011). Activation
of HIF1a transcriptional activity by multiple growth stimuli and
hypoxia is mediated by STAT3 (Gray et al, 2005; Lang et al, 2007).
Thus, through the action of STAT3, HIF1a upregulates genes
involved in enhanced cell proliferation and survival (Lang et al,
2007). Our study showed that PIAS4 siRNA decreased or delayed
the induction of HIF1a expression, and suppressed phosphoryla-
tion levels of STAT3. After 48 h of hypoxia, STAT3 remained
suppressed and was not reactivated suggesting an additional
non-HIF1a-dependent mechanism of STAT3 regulation by PIAS4
in these pancreatic cancer cells. In addition to STAT3, STAT5a and
5b have also been implicated in pancreatic tumourigenesis
(Kataoka et al, 2007; Moser et al, 2012). Although a previous
study showed weak positive staining of STAT5b in normal
pancreatic ducts adjacent to the tumour and 50% of tumour
samples exhibited positive staining for STAT5b (Moser et al, 2012),
no phosphorylated STAT5a or 5b were detected in BxPc3 cells
suggesting at least for the pancreatic cancer cells STAT3 has a more
prominent role in the context of PIAS4. Phosphorylation of STAT3
is mediated by the Janus-activated kinase (JAK) (Zhong and
Darnell, 1994); and in a KRAS-induced mouse model of PDAC, a
selective JAK2 inhibitor blocked STAT3 phosphorylation and
reduced the formation of pancreatic intraepithelial neoplasms and
adenocarcinomas (Corcoran et al, 2011). Prior studies have found
that the endogenous JAK2 inhibitor protein tyrosine phosphatase
1B (PTP1B) can become sumoylated and inactivated in mamma-
lian fibroblasts (Dadke et al, 2007). The PIAS4 siRNA knockdown
cells showed a global decrease in SUMO1 levels. Potentially,
PTP1B may be a substrate of PIAS4 sumoylation resulting
in increased JAK2 activity with subsequent phosphorylation
of STAT3. Therefore, the JAK/STAT pathway in PDAC may be
suppressed by PIAS4 siRNA.
Our observation of either decreased or delayed HIF1a induction
in PIAS4 siRNA knockdown pancreatic cancer cells was likely due
to the decreased sumoylation of VHL. Von Hippel–Lindau acts as a
tumour suppressor by degradation of HIF1a (Kaelin, 2008). Von
Hippel–Lindau sumoylation inactivates its tumour-suppressing
activity (Cai et al, 2010). Coimmunoprecipitation assays demon-
strated that the functional interaction between PIAS4 and VHL is
essential for regulation of HIF1a activity. We showed that loss of
binding between PIAS4 and two mutant VHL constructs reduced
HIF1a transcriptional activity as demonstrated by luciferase assays.
In addition, although the VHL mutant R167Q did not interfere
with binding between PIAS4 and VHL, it was still able to suppress
HIF1a transcriptional activity. This amino acid is a part of the
alpha helix containing domain involved in interaction between
VHL and elongin BC complex that targets HIF1a for proteasomal
degradation (Iwai et al, 1999). How this mutation decreased the
transcriptional activity of HIF1a requires further study. On the
basis of our results, we present a mechanism for the role of
PIAS4 in pancreatic cancer (Figure 8). The model illustrates that in
the hypoxic condition, PIAS4 sumoylates and inactivates VHL
which leads to HIF1a activation. Hypoxia also induces PIAS4
expression. In normoxic condition, PIAS4 alone is sufficient to
activate STAT3, NFkB, ERK and subsequently transcriptional
activation of MYC, Cyclin D1, VEGF, and JMJD1A. As a result,
pancreatic cancer cell proliferation, angiogenesis, and metastasis
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Figure 7. Regulation of HIF1a activity by interaction between PIAS4
and VHL. Panc1 cells were co-transfected with PIAS4 and a series of
VHL constructs expressing either wild-type (pCSVHL-WT) or mutant
VHL (pCSVHL-W88S, pCSVHL-Y112H, pCSVHL-R167Q). W88S and
Y112H are located inside and R167Q outside of the PIAS4-binding
domain. (A) Coimmunoprecipitation assay. Immunoprecipitation (IP)
with PIAS4 antibodies and blotted (IB) with either VHL or PIAS4
antibodies. Western blot analysis of total lysates was used to examine
VHL expression. (B) Hypoxia-response element reporter assays. Cells
were co-transfected with the HRE-LUC reporter construct, PIAS4, and
VHL expression vectors as indicated. HRE-LUC reporter activity was
normalised to Renilla activity and calculated as relative light units. HRE-
LUC contains three repeats of the hypoxia-response element upstream
of the thymidine kinase minimal promoter driving the firefly luciferase
reporter gene. Results represent the mean of two independent
experiments, each with triplicate wells.
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are promoted. In summary, our study demonstrated the essential
role of PIAS4 in the regulation of pancreatic cancer cell growth by
VHL sumoylation and enhanced HIF1a activity. Our data strongly
suggest that inhibition of PIAS4 activity can be a novel therapeutic
approach in the management of pancreatic cancers.
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